Verona Pharma

$8.22
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.16 (-1.91%) Today

$0.00 (0.00%) As of 12:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Verona Pharma and other stocks, options, and ETFs commission-free!

About VRNA

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound.

CEO

David S. Zaccardelli

Employees

Headquarters

London, Greater London

Founded

2005

Market Cap

490.64M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

90.02K

High Today

$8.42

Low Today

$8.06

Open Price

$8.42

Volume

16.86K

52 Week High

$15.71

52 Week Low

$3.70

VRNA Earnings

-$1.09

-$0.73

-$0.36

$0.00

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Q1 FY21

Estimated

— per share

Actual

Expected Apr 29, Pre-Market